Pharmaron Beijing Co., Ltd. (300759.SZ) has released its annual performance forecast for 2025, anticipating a net profit attributable to the shareholders of the listed company in the range of 1.614 billion to 1.686 billion yuan, representing a year-on-year decrease of 6% to 10%.

According to the company's preliminary calculations, non-recurring gains and losses attributable to shareholders for the 2025 fiscal year are estimated to be approximately 110 million to 130 million yuan, primarily comprising government grants recognized in current profit or loss, fair value change gains from other non-current financial assets, and gains or losses related to investments in low-to-medium risk bank wealth management products.